Reclassfying Estrogen Receptor-Positive/Basal Subtype by Using Immunohistochemistry Itself According to Grade and Estrogen Receptor Positivity Might Be Possible

Affiliations

Comment

Kadri Altundag. JCO Precis Oncol. 2022 Aug.

. 2022 Aug:6:e2200242.

doi: 10.1200/PO.22.00242.

No abstract available

Comment in

Reply to W. Altundag.
Audeh W. Audeh W. JCO Precis Oncol. 2022 Aug;6:e2200315. doi: 10.1200/PO.22.00315. JCO Precis Oncol. 2022. PMID: 35952323 No abstract available.

Distinct Neoadjuvant Chemotherapy Response and 5-Year Outcome in Patients With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Tumors That Reclassify as Basal-Type by the 80-Gene Signature.
Whitworth PW, Beitsch PD, Pellicane JV, Baron PL, Lee LA, Dul CL, Murray MK, Gittleman MA, Budway RJ, Rahman RL, Kelemen PR, Dooley WC, Rock DT, Cowan KH, Lesnikoski BA, Barone JL, Ashikari AY, Dupree BB, Wang S, Menicucci AR, Yoder EB, Finn C, Corcoran K, Blumencranz LE, Audeh W; NBRST Investigators Group. Whitworth PW, et al. JCO Precis Oncol. 2022 Apr;6(1):e2100463. doi: 10.1200/PO.21.00463. JCO Precis Oncol. 2022. PMID: 35476550 Free PMC article.